Syfovre Retinal Vasculitis Eye Inflammation Side Effects Causing Vision Loss
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are currently investigating Syfovre retinal vasculitis eye inflammation cases as possible Syfovre drug injury lawsuits for patients. These lawsuits would be against Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre.
Syfovre is an eye-injection drug treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It was approved by the FDA on February 17, 2023.
Syfovre side effects include occlusive retinal vasculitis, which is a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and could potentially cause blindness. There have also been reported cases of non-occlusive retinal vasculitis and other types of eye inflammation.
To date, all reported Syfovre adverse events causing these vision problems began one to two weeks after a patient’s first Syfovre injection.
We encourage you to submit a Syfovre Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Syfovre drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his more than 20 years of experience handling drug injury cases.
Most Recent Article About Syfovre
We have some new information about Syfovre eye injections adverse reactions causing vision loss and blindness from Apellis Pharmaceuticals and the American Society of Retina Specialists (ASRS).
Apellis said that it has confirmed seven cases of Syfovre eye injections adverse reactions. More specifically, these Syfovre vision loss cases involve a type of eye inflammation called retinal vasculitis. Four Syfovre patients have developed occlusive retinal vasculitis, a possibly blinding condition in which blood flow to the retina is blocked.
The ASRS shared a timeline of events related to these cases of Syfovre eye injections adverse reactions, as outlined below:
To read more of this article, click below:
- July 3, 2023: The first report of panuveitis with retinal occlusive vasculitis was received by the ASRS Research and Safety in Therapeutics (ReST) Committee.
- July 5, 2023: ReST contacted Apellis to discuss safety concerns arising from this first Syfovre vision loss case.
- July 6-12, 2023: The ASRS received six additional reports of Syfovre eye injections adverse reactions in patients.
- July 12, 2023: Apellis and the ASRS Research and Safety in Therapeutics (ReST) Committee met to discuss severe intraocular inflammation and cases of vasculitis in patients who had received Syfovre eye injections.
- July 15, 2023: The ASRS Executive Committee unanimously approved the Syfovre safety concerns “communication”, which was agreed to by Apellis and sent to ASRS members that same day.
It has been reported by medical news sources that as of late July 2023, Apellis does not know the cause, yet, for these seven cases of Syfovre eye injections adverse reactions. Further, Apellis has said that so far the company has only been able to rule out drug product quality and manufacturing issues.
As such, other possible causes for these Syfovre vision loss cases involving retinal vasculitis remain to be researched.
We are investigating Syfovre vision loss cases as drug injury lawsuits against Apellis for patients who developed occlusive retinal vasculitis or eye inflammation after receiving a Syfovre eye injection.[Read article in full at original source]
Earlier articles about Syfovre by attorney Tom Lamb on the Side Effects Blog:
- Syfovre Vision Loss Cases Reported In Patients After First Injection
- Syfovre Occlusive Retinal Vasculitis Cases Warning Letter July 2023